• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    6/29/26 5:01:30 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCLX alert in real time by email
    8-K
    0001820190false0001820190sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf40250PerShareMember2026-06-242026-06-240001820190sclx:CommonStockParValue00001PerShare2Member2026-06-242026-06-2400018201902026-06-242026-06-24

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _______________________

    FORM 8-K
    _______________________

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): June 24, 2026

    _______________________

    SCILEX HOLDING COMPANY
    (Exact name of registrant as specified in its charter)

    _______________________

    Delaware
    (State or other jurisdiction
    of incorporation)

    001-39852
    (Commission
    File Number)

    92-1062542
    (IRS Employer
    Identification No.)

     

    960 San Antonio Road, Palo Alto, California, 94303
    (Address of principal executive offices, including zip code)

    (650) 516-4310

    Registrant’s telephone number, including area code

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    _______________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

    (Title of each class)

    (Trading Symbol)

    (Name of exchange on which registered)

    Common Stock, par value $0.0001 per share

    SCLX

    The Nasdaq Stock Market LLC

    Warrants to purchase one share of common stock, each at an exercise price of $402.50

    SCLXW

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


     

    Item 1.01. Entry into a Material Definitive Agreement.

    On June 24, 2026, Scilex Holding Company (the “Company”) entered into a binding term sheet (the “Term Sheet”) with Datavault AI Inc. (“Datavault”), which sets forth certain terms and conditions of the Company’s proposed purchase (the “Proposed Transaction”) of Bitcoin (“BTC”) from Datavault that is currently held by Datavault in a Biconomy digital wallet (the “Wallet”).

     

    Pursuant to the Term Sheet, and subject to the finalization of a definitive agreement (the “Definitive Agreement”) to be negotiated in good faith by the Company and Datavault and, ultimately, the satisfaction of certain customary closing conditions to be contained therein, it is expected that the Company will purchase from Datavault a total of 837 BTC held in the Wallet for $50 million (the “Purchase Price”). The Company has agreed to make an initial payment of $30 million, with the remaining $20 million payable in quarterly installments commencing in the fourth quarter of 2026 and ending on December 31, 2028. The Company will pay the Purchase Price in cash or shares of the Company’s common stock, par value $0.0001 per share (“Company Common Stock”) or publicly traded securities of the Company’s subsidiaries, or a combination thereof, at the discretion of the Company.

     

    The Term Sheet provides that the Definitive Agreement will contain customary representations, warranties, covenants, indemnities, limitations on indemnity, termination provisions and other terms typical for transactions of this nature.

    There can be no assurance that the Definitive Agreement and any other transaction documents necessary to consummate the Proposed Transaction will be entered into, or that the Proposed Transaction will be consummated on the terms described herein or at all. The consummation of the Proposed Transaction is subject to numerous factors, many of which are outside the control of the Company, including market conditions, regulatory approvals, the actions of third parties, and the ability of the parties to negotiate and execute the Definitive Agreement. The Term Sheet reflects terms that remain subject to further negotiation, modification and/or approval by the applicable boards of directors and may be terminated by the parties. Any such termination, or a failure by the parties to agree on the Definitive Agreement, could result in disputes or litigation relating to the interpretation, enforceability and/or performance of the provisions of the Term Sheet, which could be costly and/or time-consuming, divert management attention and/or otherwise adversely affect the financial condition or liquidity of the Company, including its ability to pursue or defend such claims. Accordingly, investors should not place undue reliance on the consummation of the Proposed Transaction or the ability of the Company and Datavault to consummate the Proposed Transaction.

    The foregoing description of the Term Sheet does not purport to be complete and is qualified in its entirety by reference to the full text of the Term Sheet, a copy of which the Company will file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026 or by an amendment to this Current Report on Form 8-K.

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    The information provided in Item 1.01 regarding the Term Sheet and the potential issuance of shares of Company Common Stock is hereby incorporated by reference.

     

    It has not yet been determined whether the shares of Company Common Stock that may be issued in the Proposed Transaction will be issued in a private placement. If such shares are issued in a private placement, the Company expects that (i) such shares would be issued to Datavault in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder and (ii) Datavault will represent that it is an “accredited investor,” as defined in Regulation D, and will acquire such shares for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. Neither this Current Report on Form 8-K nor the Term Sheet is an offer to sell or the solicitation of an offer to buy shares of Company Common Stock or any other securities of the Company.

    2

     


     

     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SCILEX HOLDING COMPANY

     

     

     

     

    By:

    /s/ Henry Ji, Ph.D.

     

    Name:

    Henry Ji, Ph.D.

    Date: June 29, 2026

    Title:

    Chief Executive Officer & President

     

    3

     


    Get the next $SCLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCLX

    DatePrice TargetRatingAnalyst
    1/27/2025$22.00Buy
    D. Boral Capital
    10/16/2024$14.00Buy
    Alliance Global Partners
    6/13/2024$13.00Buy
    Rodman & Renshaw
    10/16/2023$4.00Buy
    B. Riley Securities
    10/13/2023$4.00Buy
    B. Riley Securities
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026

    PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") commence trading on the Biconomy Exchange on July 6, 2026. To view the Dream Bowl Tokens now trading on the Biconomy Exchange, please click https://www.biconomy.com/exchange/DREAM1_USDT.  Scilex believes that the ability to trade the Dream Bowl Tokens may deliver liquidity

    7/6/26 11:35:25 AM ET
    $SCLX
    $DVLT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Semiconductors
    Technology

    Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP

    PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 of newly issued shares of Scilex common stock. The purchase price for such shares is expected to be $15.00 per share,

    7/6/26 6:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    12/18/24 7:04:41 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/31/24 12:44:57 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    10/29/24 6:59:31 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    SEC Filings

    View All

    Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scilex Holding Co (0001820190) (Filer)

    7/6/26 6:15:40 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Scilex Holding Co (0001820190) (Filer)

    6/29/26 5:01:30 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Scilex Holding Co (0001820190) (Filer)

    6/24/26 4:52:59 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    D. Boral Capital initiated coverage on Scilex Holding with a new price target

    D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

    1/27/25 8:08:33 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Scilex Holding with a new price target

    Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

    10/16/24 8:01:57 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

    Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

    6/13/24 7:16:15 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Issuer)

    7/7/26 9:25:20 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Scilex Holding Co disposed of 7,034,737 shares (SEC Form 4)

    4 - Scilex Holding Co (0001820190) (Reporting)

    6/26/26 4:19:45 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Ma Stephen Hoi

    4 - Scilex Holding Co (0001820190) (Issuer)

    4/20/26 8:56:24 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Financials

    Live finance-specific insights

    View All

    Scilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

    PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the "Payment Date") for the dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participating Holders") that held such securities as of the r

    6/12/26 7:45:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities

    PALO ALTO, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") has set June 15, 2026 as the payment date (the "Payment Date") for the previously announced dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible holders of Scilex securities (collectively, the "Participati

    6/4/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026

    PALO ALTO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its board of directors (the "Board") approved a dividend of Semnur Pharmaceuticals, Inc. ("Semnur") (OTC:SMNR) common stock held by the Company to its stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders"). The record date for the dividend is June 1, 2026 (the "Record Date"). Th

    5/22/26 1:15:00 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Leadership Updates

    Live Leadership Updates

    View All

    Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

    Significant Appreciation in Alpha Tau (NASDAQ:DRTS) Position (up ~$128 Million)Scilex (NASDAQ:SCLX) Loan Substantially RepaidTotal Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026)Oramed to Join the Russell 2000 and Russell 3000 Indexes this weekNEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repa

    6/25/26 11:35:00 AM ET
    $ORMP
    $DRTS
    $SCLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel

    PALO ALTO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced that it has appointed Kasowitz LLP and its founding partner Marc Kasowitz as the Company's litigation and intellectual property counsel. Kasowitz LLP will advise Scilex on complex commercial litigation, patent litigation, intellectual property enforcement and defense, licensing matters, and strategic intellectual property governance as the C

    1/2/26 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

    7/23/24 9:00:00 AM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    4/25/24 5:25:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

    SC 13D/A - Scilex Holding Co (0001820190) (Subject)

    3/5/24 4:22:28 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care